Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
22 Marzo 2023 - 1:21PM
Edgar (US Regulatory)
Filed
Pursuant to Rule 424(b)(5)
Registration No. 333-258687
PROSPECTUS
SUPPLEMENT
(To Prospectus
and Prospectus Supplement,
each dated
August 19, 2021)
$9,868,603
Common
Stock
This prospectus
supplement amends and supplements the information in our prospectus, dated August 19, 2021 (File No. 333-258687), or the
Base Prospectus, and the shelf registration statement on Form S-3 of which the Prospectus is a part, or the Registration
Statement, and our Prospectus Supplements dated August 19, 2021 and March 18, 2022, which, together with the Base Prospectus, we refer
to as the Prospectus, filed under the Registration Statement for the offer and sale of shares of our common stock having an aggregate
offering price of up to $75,000,000 under the Sales Agreement (as defined below). This prospectus supplement should be read in conjunction
with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the
information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in
connection with, the Prospectus and any future amendments or supplements thereto.
In accordance
with the terms of the Controlled Equity OfferingSM sales agreement (the “Sales Agreement”), dated
August 10, 2021, we entered into with Cantor Fitzgerald & Co., or Cantor, and RBC Capital Markets, LLC, or RBC, we may offer
and sell shares of our common stock from time to time through Cantor and RBC, acting as sales agents, or the Sales Agents.
We are now
subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement of which
this prospectus supplement and the Prospectus form a part. The aggregate market value of our common stock held by non-affiliates pursuant
to General Instruction I.B.6 of Form S-3 is $29,605,810, which was calculated based on 7,401,453 shares of our outstanding common stock
held by non-affiliates on March 20, 2023, at a price of $4.00 per share, the closing price of our common stock on January 25, 2023. During
the 12 calendar months prior to, and including, the date of this prospectus supplement, we sold securities with an aggregate market value
of $789,728 pursuant to General Instruction I.B.6 of Form S-3. As a result of the limitations of General Instruction I.B.6, and in accordance
with the terms of the sales agreement, we are registering the offer and sale of shares of our common stock having an aggregate offering
price of up to $9,868,603 from time to time through the Sales Agents.
Our common
stock is listed on the Nasdaq Global Market under the symbol “MRKR.” On March 21, 2022, the last reported sales price of
our common stock was $1.76 per share.
Investing
in our common stock involves risks. Before buying any shares, you should read the discussion of material risks of investing in our common
stock in “Risk Factors” beginning on page 2 of the Prospectus, and in the risks discussed under similar headings in
the documents incorporated by reference in this prospectus supplement and the Prospectus, as they may be amended, updated or modified
periodically in our reports filed with the Securities and Exchange Commission.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus supplement and the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Cantor |
​ |
​ |
RBC
Capital Markets |
The
date of this prospectus supplement is March 22, 2023.
Grafico Azioni Marker Therapeutics (NASDAQ:MRKR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Marker Therapeutics (NASDAQ:MRKR)
Storico
Da Giu 2023 a Giu 2024